Bicycle Therapeutics (NASDAQ:BCYC) Shares Down 5.8%

Bicycle Therapeutics plc (NASDAQ:BCYC) fell 5.8% during mid-day trading on Friday . The company traded as low as $23.00 and last traded at $23.08. 469,718 shares changed hands during trading, an increase of 23% from the average session volume of 381,422 shares. The stock had previously closed at $24.49.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BCYC. HC Wainwright lowered their price target on Bicycle Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, February 21st. Canaccord Genuity Group restated a “buy” rating and issued a $60.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 21st. Finally, Needham & Company LLC restated a “buy” rating and issued a $43.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.88.

Bicycle Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.08 and a current ratio of 8.08. The stock has a market capitalization of $693.32 million, a price-to-earnings ratio of -4.76 and a beta of 0.89. The company has a 50-day moving average of $23.68 and a 200-day moving average of $19.27.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Tuesday, February 20th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.07. The firm had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $11.68 million. Bicycle Therapeutics had a negative net margin of 669.72% and a negative return on equity of 57.80%. As a group, equities research analysts expect that Bicycle Therapeutics plc will post -5.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Kevin Lee sold 3,158 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total value of $75,191.98. Following the sale, the chief executive officer now owns 387,270 shares in the company, valued at approximately $9,220,898.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 5,312 shares of company stock worth $126,139 in the last quarter. 10.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. BluePath Capital Management LLC acquired a new stake in Bicycle Therapeutics during the third quarter valued at approximately $31,000. Tower Research Capital LLC TRC increased its stake in shares of Bicycle Therapeutics by 109.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,263 shares of the company’s stock worth $53,000 after purchasing an additional 1,184 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Bicycle Therapeutics by 118.9% during the 2nd quarter. Osaic Holdings Inc. now owns 2,320 shares of the company’s stock worth $59,000 after purchasing an additional 1,260 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Bicycle Therapeutics during the 2nd quarter worth $60,000. Finally, Natixis acquired a new position in Bicycle Therapeutics in the 4th quarter valued at $107,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.